We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Takeda Pharmaceutical Co Ltd | LSE:0RN3 | London | Ordinary Share | JP3463000004 | TAKEDA PHARMACEUTICAL ORD SHS |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | JPY 4.05T | JPY 317.02B | JPY 200.3525 | 0.25 | 78.09B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 49.35 | EUR |
Date | Time | Source | Headline |
---|---|---|---|
22/4/2024 | 20:41 | ALNC | Takeda, Astellas and Sumitomo to create new drug discovery company |
09/11/2023 | 12:16 | ALNC | Hutchmed hails Takeda's fruquintinib approval from US for cancer form |
30/10/2023 | 12:24 | ALNC | Takeda Pharmaceutical first half profit falls as costs outpace revenue |
29/9/2023 | 10:12 | ALNC | Hutchmed notes Takeda submits fruquintinib drug application in Japan |
27/7/2023 | 10:26 | ALNC | Takeda keeps guidance unchanged despite drop in quarterly profit |
12/7/2023 | 13:22 | ALNC | Japan's Takeda pulls dengue vaccine candidate in US |
12/7/2023 | 05:16 | ALNC | Japan's Takeda pulls dengue vaccine candidate in US |
16/6/2023 | 08:51 | ALNC | Hutchmed, Takeda Fresco-2 study published in The Lancet |
11/5/2023 | 11:51 | ALNC | TOP NEWS: Takeda outlook downbeat as Covid wanes, hit from generics |
Takeda Pharmaceutical (0RN3) Share Charts1 Year Takeda Pharmaceutical Chart |
|
1 Month Takeda Pharmaceutical Chart |
Intraday Takeda Pharmaceutical Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions